The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.
Edith P. Mitchell
Honoraria - Sanofi
Research Funding - Genentech
Michael J. Guarino
No relevant relationships to disclose
Michael L. Andria
Employment or Leadership Position - Regeneron
Pankaj Bhargava
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Jeffrey J. Kirshner
No relevant relationships to disclose